Expand ATNM Menu
ATNM MENU

ATNM Latest Press Releases

-- June 3, 2026 --

Actinium Presents New ATNM-400 Data in KRAS and EGFR Mutant Models at SNMMI 2026 Supporting a Mutation-Agnostic Opportunity In Non-Small Cell Lung Cancer PRNewswire 8:00 AM
Actinium Pharmaceuticals Oral Presentation at SNMMI 2026 Highlights ATNM-400 Overcoming Resistance to All Three Approved Androgen Receptor Inhibitors and Offers Flexible, Well-Tolerated Dosing in Prostate Cancer Models PRNewswire 7:25 AM

-- June 1, 2026 --

Actinium Appoints Accomplished Oncology Expert Steffen Heeger MD, MSc as Chief Medical Officer to Drive Rejuvenated Pipeline Development PRNewswire 8:00 AM
Actinium Pharmaceuticals Presents New Radiochemistry Data at SNMMI 2026 Demonstrating That CAR Optimization Improves Tumor Targeting and Pharmacokinetics of Actinium-225 Radioconjugates PRNewswire 7:00 AM

-- May 29, 2026 --

Actinium Pharmaceuticals Receives Two Patent Allowances Spanning Its Actimab-A and Iomab-ACT Programs PRNewswire 5:31 PM
Actinium Pharmaceuticals to Present ATNM-400 Program Update at SNMMI 2026 Conference on May 31-June 2 and Provides NYSE American Listing Standards Notice PRNewswire 5:30 PM

-- May 6, 2026 --

Actinium Pharmaceuticals Announces Three SNMMI 2026 Presentations Highlighting Differentiated Profile of ATNM-400 Across Lung and Prostate Cancer and Radioconjugate Optimization PRNewswire 5:34 PM

-- April 22, 2026 --

Actinium Highlights Transcriptional Reprogramming as a Key Mechanism Underpinning Mutation-Agnostic Activity of Actimab-A in AML at the 2026 American Association of Cancer Research Annual Meeting PRNewswire 7:00 AM
Actinium Pharmaceuticals, Inc. Announces Compelling Pan-Tumor Data for ATNM-400 Demonstrating Broad Efficacy Across Prostate, Lung, and Breast Cancer Models at the 2026 American Association of Cancer Research Annual Meeting PRNewswire 7:00 AM

-- April 6, 2026 --

Actinium Pharmaceuticals Announces New Pan-Tumor Preclinical Data for ATNM-400 in Solid Tumors and Differentiated Mechanism for Actimab-A in AML to be Presented at 2026 AACR Annual Meeting PRNewswire 7:30 AM

-- February 17, 2026 --

Actinium Pharmaceuticals, Inc. to Present Two Abstracts at the 2026 AACR Annual Meeting PRNewswire 7:43 AM
Market Data Delayed 15 Minutes